Address: 1 Libertas Road
Cnr Main Road and Sloane Street
Tel: +27 (0) 11 514 3000
The South African arm of Nycomed has its origins in 1996 when two German companies, Byk Gulden and Madaus AG entered into a joint venture in South Africa and Byk Madaus was created. All products were managed in one combined portfolio and came from either Byk Gulden, Madaus or were in-licenced from other companies. Packaging, warehousing and distribution operations were carried out at a warehouse facility in Midrand.
In 2001, the company outsourced its distribution to PHD.
In 2002, Altana Pharma was launched when Altana bought out the Byk portion of the Byk Madaus joint venture.
In 2003 a further name change took place and the company became the South African joint venture known as Altana Madaus. It was during this period that a separate OTC and Rx division were launched, the Midrand facility was sold and the company moved from Midrand to Woodmead.
In 2007 Nycomed GmbH acquired Altana Pharma and Rottapharm acquired Madaus GmbH. A further name change took place and the local company became known as Nycomed Madaus.
In 2008, Nycomed GmbH acquired the Madaus 50% share of the joint venture and the South African business now falls under the sole control of the Nycomed group of companies.
The South African product range encompasses both licensed and in-licensed OTC (Over the Counter) and Rx (prescription) products. These products are marketed and distributed nationally.
The Rx* product range covers the following treatment areas:
Pain and Inflamation
* In terms of South African legislation, scheduled products may not be marketed to the public and the brands have therefore not been mentioned on this website
The OTC product range encompasses the following treatment areas and products:
Laxatives – Agiolax® and Agiobulk®
Tranquiliser – Biral®
Pain and Inflammation – Empaped®, Reparil®, Dona®
Vitamin and Mineral – Emvit®, Emvit®.M, Emvit® Cal-D3, Magnesit®
Iron – Ferrimed®
Sun care – Piz Buin®
A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock…
With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government…
The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s…
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed…
As COVID-19 threatens to derail more than a decade’s worth of hard-won gains in the fight against malaria, Dr…
The South African affiliate of Indian pharma firm Cipla will begin manufacturing and distribution of remdesivir, a…
Below is a roundup of latest news from South Africa’s life sciences and healthcare industries, including a…
Kelly du Plessis is CEO & Founder of Rare Diseases South Africa, a registered NPO born out of necessity when…
Trailing behind South Africa’s pharmaceutical market in both value and growth, the nation’s medical device…
The traditional model of healthcare has generally been limited to treatment in health facilities. But, when it…
Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease…